IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

<u>IN TI</u>	HE UNITED STA	ATES DESIGN	NATED/ELECTED OFFICE				
tional Appl	ication No.	:	PCT/EP02/14389				
tional Filin	nal Filing Date : December 17, 2002						
y Date(s) Cl	aimed	:	January 17, 2002				
ant(s) (DO/	EO/US)	:	Guenter HOELZEMANN et al				
	Y-PIPERIDINES I A AND DEPRES		ATMENT OF DISEASES SUCH AS				
RMATION	DISCLOSURE	STATEMENT	T UNDER 37 CFR §§ 1.56, 1.97 and 1.98				
issioner for ox 1450 Idria, VA 22							
8 as follow	nation disclosure s s:	tatement is mad	le in accordance with 37 C.F.R. §§ 1.56, 1.97				
and Fees							
Under 37 (disclosure	C.F.R. § 1.97(b), statement is filed:	no fee or stater	ment is required for filing this information				
	within three months of the filing date of a national application other than a CPA under § 1.53(d);						

International Application No. PCT/EP02/14389

International Filing Date December 17, 2002

Priority Date(s) Claimed January 17, 2002

Applicant(s) (DO/EO/US) Guenter HOELZEMANN e

Title: PHENOXY-PIPERIDINES FOR THE TREATMENT OF DISEASES ST SCHIZOPHRENIA AND DEPRESSION

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

 \boxtimes

This information disclosure statement is made in accordance with 37 C.F.R and 1.98 as follows:

Timing and Fees

disclosure statement is filed:					
		three months of the filing date of a national application other than a CPA § 1.53(d);			
\boxtimes		three months of the actual filing date of the national phase of a PCT ration; OR			
	before RCE).	e the mailing of a first substantive office action (including after filing of an			
Under specif	:37 C.F ied in 3	.R. § 1.97(c), this information disclosure statement is filed after the periods 7 C.F.R. § 1.97(b), but before the mailing date of:			
		a final rejection under 37 C.F.R. 1.113;			
		termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR			
		a notice of allowance under 37 C.F.R. § 1.311; and			

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
			a final action under 37 C.F.R. § 1.113;
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
			a notice of allowance under 37 C.F.R. § 1.311;
	AND i	is filed	on or before payment of the issue fee; AND is accompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).
Staten	nents Ui	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	Materia	<u>ls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	\boxtimes		s of materials listed but not attached were cited in an international search dated March 20, 2003.
		Copies	s of the materials listed are attached (except for the foregoing).

Non-English	Language References
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
\boxtimes	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document
	 A = document defining the general state of the art O = non-written disclosure P = intercalated document
	T = document cited to understand the theory or principle underlying the invention
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
	D = cited in the application
	L = cited for another reason & = publication of member of same patent family
\boxtimes	Translation of other relevant information on foreign search report
	In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure.
Other Inform	ation_
Payment of F	ees Due (If Any):

Please charge to Deposit Account No. 13-3402 \$

covering the fee identified above is attached.

for the fee identified above.

A check for \$

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2903

Date: July 19, 2004

AJZ:aap

K:\Merck\2903\Information Disclosure Statement.doc

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
prespond to a collection of information unless it contains a valid OMB control number.

Substitute for	r form 1449A/PT(0		Complete if Known			
				Application Number	Unassigned 10/5017		
INFOR	MATION	DIS	CLOSURE	Filing Date	July 19, 2004		
STATEMENT BY APPLICANT				First Named Inventor	Guenter HOELZEMANN et al.		
				Group Art Unit	Unassigned		
(use as many sheets as necessary)				Examiner Name	Unassigned		
Sheet	1	of	2	Attorney Docket Number	MERCK-2903		

	U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.1	U.S. Patent Document Kind Code ² e No. ¹ Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	1	2776293		Joseph Levy et al.	January 1, 1957			
	2	5202346		Butera John A. et al.	April 13, 1993			
	3	5169855			August 12, 1992			
			1					


	FOREIGN PATENT DOCUMENTS								
		Foreign Patent Document				Date of Publication of	Pages, Columns, Lines, Where Relevant		
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	т⁵	
	4	EP	0449187		DU PONT MERCK PHARMA	October 2, 1991		Equv to cite 3	
············		!		-					
								·	
	-		-						

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.



of

2

Sheet

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO Application Number Unassigned INFORMATION DISCLOSURE July 19, 2004 🥌 Filing Date STATEMENT BY APPLICANT Guenter HOELZEMANN et al. First Named Inventor Group Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned **MERCK-2903** Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	5	DATABASE CA 'ONLINE! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TANG, WEI-FANG ET AL: "STUDIES OF ETHERIFICATION OF 1-SUBSTITUTED PHENYLETHYL-4- HYDROXYPIPERIDINES" RETRIEVED FROM STN DATABASE ACCESSION NO. 133:207639 XP002233662.	
	6	LARSEN S.D. ET AL: "REACTIONS OF ALLYLSILANES WITH SIMPLE IMINIUM SALTS IN WATER: A FACILE ROUTE TO PIPERIDINES VIA AN AMINOOMETHANO DESILYLATION-CYCLIZATION PROCESS" J.A.CHEM.SOC., Bd. 108, 1986 XP002233646.	
	7	LLOYD W. ET AL: "SOME OBSERVATIONS RELATING TO THE USE OF 1-ARYL-4-ALKOXYPIPERIDIN-4-YL GROUPS FOR THE PROTECTION OF THE 2'-HYDROXY FUNCTIONS IN THE CHEMICAL SYNTHESIS OF OLIGORIBONUCLEOTIDES" J. CHEM. SOC., PERKIN TRANS. 1, Bd. 2, 2000 XP002233647.	
	8	DATABASE CROSSFIRE BEILSTEIN 'ONLINE! BEILSTEIN INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; DATABASE ACCESSION NO. BRN 169581,BRN 168865,BRN 146735 XP002233649.	
			_
	-		
			<u> </u>
	-		
	†		

Examiner	Date	
CAMITITIE		
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.